Lyme disease is a bacterial infection transmitted to humans through the bite of infected ticks. While the disease can be effectively treated with antibiotics, some patients continue to experience symptoms long after the infection has been eradicated. This condition, known as Post Treatment Lyme Disease (PTLD), affects approximately 14% of patients who have been treated for Lyme disease.
Researchers at Northwestern University have made a breakthrough in understanding why some patients develop PTLD. They have found that remnants of the Borrelia burgdorferi bacteria, which causes Lyme disease, may linger in the liver even after antibiotic treatment. These remnants, specifically a structural component called peptidoglycan, can trigger an inappropriate immune response in some individuals, leading to persistent symptoms.
Peptidoglycan is a common target of antibiotics and is present in the cell walls of many bacteria, including Borrelia burgdorferi. However, the peptidoglycan from Lyme disease bacteria is structurally unique and can evade the body’s natural clearance mechanisms. This can lead to chronic inflammation and ongoing symptoms such as fatigue, cognitive difficulties, and joint pain.
The research, published in the journal Science Translational Medicine, shows that peptidoglycan from Lyme disease bacteria can persist in the body for weeks to months, particularly in the synovial fluid of joints. This finding may explain why some patients with Lyme arthritis do not respond to traditional antibiotic treatments but improve with anti-inflammatory medications.
Lead researcher Brandon L. Jutras, an associate professor at Northwestern University Feinberg School of Medicine, hopes that these findings will lead to better diagnostic tests and treatment options for patients with PTLD. By targeting the inflammatory response triggered by peptidoglycan, researchers may be able to develop more effective therapies for patients who continue to experience symptoms after antibiotic treatment.
Overall, this research sheds light on the underlying mechanisms of PTLD and offers new insights into how the body responds to persistent bacterial remnants. By understanding the role of peptidoglycan in driving chronic inflammation, researchers may uncover new strategies for managing and treating long-term Lyme disease symptoms.
